Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation ESC 2017

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presenter: John Eikelboom

August 27, 2017

Presentation ACC 2017

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Presenter: Magnus Ohman

March 27, 2017

Presentation CADECI 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presenter: DR. JOSE LUIS LEIVA PONS

February 20, 2015

Presentation

Efficacy, Safety of Rivaroxaban vs Warfarin in Elderly Patients with Nonvalvular A-fib

Presenter: Jonathan L. Halperin

June 09, 2014

Presentation

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Presenter: C. Michael Gibson

April 17, 2013

Presentation

Rivaroxaban in Patients Stabilized After STEMI: Results from the ATLAS ACS 2-TIMI 51 Trial

Presenter: Jessica L. Mega

March 04, 2013

Presentation TCT 2012

ATLAS ACS-2 TIMI 51: Stent thrombosis in Patients with Acute Coronary Syndromes treated with Rivaroxaban

Presenter: C. Michael Gibson

October 24, 2012

Presentation ESC 2012

Rivaroxaban in Patients following a ST-Elevation Myocardial Infarction

Presenter: Jessica L. Mega

August 27, 2012

Advertisement

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Efficacy, Safety of Rivaroxaban vs Warfarin in Elderly Patients with Nonvalvular A-fib

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Rivaroxaban in Patients Stabilized After STEMI: Results from the ATLAS ACS 2-TIMI 51 Trial

ATLAS ACS-2 TIMI 51: Stent thrombosis in Patients with Acute Coronary Syndromes treated with Rivaroxaban

Rivaroxaban in Patients following a ST-Elevation Myocardial Infarction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content